

CD272 Antibody HRP Conjugated

Catalog No: #C00354H

Package Size: #C00354H 100ul

Description

Product Name	CD272 Antibody HRP Conjugated
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Purified by Protein A.
Applications	WB IHC-P IHC-F ICC
Species Reactivity	Hu Ms Rt
Immunogen Description	KLH conjugated synthetic peptide aa 239-289 289 derived from human B and T-lymphocyte attenuator
Conjugates	HRP
Target Name	CD272
Other Names	BTLA1; CD272; B- and T-lymphocyte attenuator; B- and T-lymphocyte-associated protein; BTLA
Accession No.	Swiss-Prot#Q7Z6A9NCBI Gene ID151888
Cell Localization	Cytoplasm
Concentration	1mg ml
Formulation	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Application Details

WB=1:500-2000 IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50-200

Background

B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).

Note: This product is for in vitro research use only and is not intended for use in humans or animals.